Drug-Eluting Stent and Coronary Thrombosis
Top Cited Papers
- 27 February 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 115 (8) , 1051-1058
- https://doi.org/10.1161/circulationaha.106.675934
Abstract
Although rare, stent thrombosis remains a severe complication after stent implantation owing to its high morbidity and mortality. Since the introduction of drug-eluting stents (DES), most interventional centers have noted stent thrombosis up to 3 years after implantation, a complication rarely seen with bare-metal stents. Some data from large registries and meta-analyses of randomized trials indicate a higher risk for DES thrombosis, whereas others suggest an absence of such a risk. Several factors are associated with an increased risk of stent thrombosis, including the procedure itself (stent malapposition and/or underexpansion, number of implanted stents, stent length, persistent slow coronary blood flow, and dissections), patient and lesion characteristics, stent design, and premature cessation of antiplatelet drugs. Drugs released from DES exert distinct biological effects, such as activation of signal transduction pathways and inhibition of cell proliferation. As a result, although primarily aimed at preventing vascular smooth muscle cell proliferation and migration (ie, key factors in the development of restenosis), they also impair reendothelialization, which leads to delayed arterial healing, and induce tissue factor expression, which results in a prothrombogenic environment. In the same way, polymers used to load these drugs have been associated with DES thrombosis. Finally, DES impair endothelial function of the coronary artery distal to the stent, which potentially promotes the risk of ischemia and coronary occlusion. Although several reports raise the possibility of a substantially higher risk of stent thrombosis in DES, evidence remains inconclusive; as a consequence, both large-scale and long-term clinical trials, as well as further mechanistic studies, are needed. The present review focuses on the pathophysiological mechanisms and pathological findings of stent thrombosis in DES.Keywords
This publication has 55 references indexed in Scilit:
- Pioglitazone Inhibits In-Stent Restenosis in Atherosclerotic Rabbits by Targeting Transforming Growth Factor-β and MCP-1Arteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Effects of Tacrolimus or Sirolimus on Proliferation of Vascular Smooth Muscle and Endothelial CellsJournal of Cardiovascular Pharmacology, 2006
- Dimethyl Sulfoxide Inhibits Tissue Factor Expression, Thrombus Formation, and Vascular Smooth Muscle Cell ActivationCirculation, 2006
- Frequency of and Risk Factors for Stent Thrombosis After Drug-Eluting Stent Implantation During Long-Term Follow-UpThe American Journal of Cardiology, 2006
- A Novel Drug-Eluting Stent Coated With an Integrin-Binding Cyclic Arg-Gly-Asp Peptide Inhibits Neointimal Hyperplasia by Recruiting Endothelial Progenitor CellsJournal of the American College of Cardiology, 2006
- Risk of Thrombosis With the Use of Sirolimus-Eluting Stents for Percutaneous Coronary Intervention (from Registry and Clinical Trial Data)The American Journal of Cardiology, 2005
- Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantationJournal of the American College of Cardiology, 2005
- Polymer‐Based Paclitaxel‐Eluting Stents in Percutaneous Coronary Intervention:Journal of Interventional Cardiology, 2004
- Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitroExperimental Cell Research, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003